Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles

Jan 22, 2021ACS nano

Design of a COVID-19 mRNA Vaccine Targeting the Virus’s Binding Site and Delivered by Fat-Based Particles

AI simplified

Abstract

Intramuscular administration of LNP RBD-hFc mRNA in BALB/c mice elicited a robust humoral response and a high level of neutralizing antibodies.

  • Lipid nanoparticles (LNPs) were utilized to encapsulate the SARS-CoV-2 receptor-binding domain.
  • Two leading LNP formulations were identified through a luciferase mRNA reporter assay.
  • The mRNA vaccine strategy resulted in a Th1-biased cellular response.
  • The findings suggest that these lipids could be promising candidates for mRNA vaccines targeting COVID-19.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free